DocGo (DCGO) Competitors

$0.57 -0.06 (-10.03%)

Closing price 04:00 PM Eastern

Extended Trading

$0.58 +0.01 (+1.88%)

As of 05:30 PM Eastern

DCGO vs. LFMD, AIRS, BNR, NAKA, and BDSX

Should you be buying DocGo stock or one of its competitors? The main competitors of DocGo include LifeMD (LFMD), AirSculpt Technologies (AIRS), Burning Rock Biotech (BNR), KindlyMD (NAKA), and Biodesix (BDSX). These companies are all part of the "healthcare" industry.

How does DocGo compare to LifeMD?

DocGo (NASDAQ:DCGO) and LifeMD (NASDAQ:LFMD) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and profitability.

DocGo has a beta of 1.02, meaning that its share price is 2% more volatile than the S&P 500. Comparatively, LifeMD has a beta of 2.03, meaning that its share price is 103% more volatile than the S&P 500.

DocGo presently has a consensus price target of $2.38, indicating a potential upside of 316.45%. LifeMD has a consensus price target of $9.14, indicating a potential upside of 91.27%. Given DocGo's higher probable upside, equities research analysts clearly believe DocGo is more favorable than LifeMD.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DocGo	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29
LifeMD	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

LifeMD has a net margin of 2.37% compared to DocGo's net margin of -56.61%. DocGo's return on equity of -34.41% beat LifeMD's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DocGo	-56.61%	-34.41%	-23.82%
LifeMD	2.37%	-176.40%	-22.61%

56.4% of DocGo shares are held by institutional investors. Comparatively, 35.5% of LifeMD shares are held by institutional investors. 3.8% of DocGo shares are held by company insiders. Comparatively, 18.4% of LifeMD shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

LifeMD has lower revenue, but higher earnings than DocGo. DocGo is trading at a lower price-to-earnings ratio than LifeMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DocGo	$322.20M	0.17	-$182.40M	-$1.85	N/A
LifeMD	$194.05M	1.17	$14.35M	$0.26	18.38

In the previous week, LifeMD had 10 more articles in the media than DocGo. MarketBeat recorded 13 mentions for LifeMD and 3 mentions for DocGo. DocGo's average media sentiment score of 0.00 beat LifeMD's score of -0.15 indicating that DocGo is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DocGo	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
LifeMD	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

LifeMD beats DocGo on 11 of the 16 factors compared between the two stocks.

How does DocGo compare to AirSculpt Technologies?

AirSculpt Technologies (NASDAQ:AIRS) and DocGo (NASDAQ:DCGO) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, dividends, valuation, profitability, earnings, institutional ownership and media sentiment.

AirSculpt Technologies has higher earnings, but lower revenue than DocGo. AirSculpt Technologies is trading at a lower price-to-earnings ratio than DocGo, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AirSculpt Technologies	$151.82M	1.79	-$11.67M	-$0.19	N/A
DocGo	$322.20M	0.17	-$182.40M	-$1.85	N/A

AirSculpt Technologies has a net margin of -7.68% compared to DocGo's net margin of -56.61%. AirSculpt Technologies' return on equity of -5.01% beat DocGo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AirSculpt Technologies	-7.68%	-5.01%	-2.19%
DocGo	-56.61%	-34.41%	-23.82%

AirSculpt Technologies has a beta of 1.99, suggesting that its stock price is 99% more volatile than the S&P 500. Comparatively, DocGo has a beta of 1.02, suggesting that its stock price is 2% more volatile than the S&P 500.

AirSculpt Technologies currently has a consensus price target of $6.00, indicating a potential upside of 55.44%. DocGo has a consensus price target of $2.38, indicating a potential upside of 316.45%. Given DocGo's stronger consensus rating and higher probable upside, analysts clearly believe DocGo is more favorable than AirSculpt Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AirSculpt Technologies	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
DocGo	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29

In the previous week, AirSculpt Technologies had 2 more articles in the media than DocGo. MarketBeat recorded 5 mentions for AirSculpt Technologies and 3 mentions for DocGo. AirSculpt Technologies' average media sentiment score of 0.00 equaled DocGo'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AirSculpt Technologies	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
DocGo	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

91.5% of AirSculpt Technologies shares are owned by institutional investors. Comparatively, 56.4% of DocGo shares are owned by institutional investors. 44.6% of AirSculpt Technologies shares are owned by insiders. Comparatively, 3.8% of DocGo shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

AirSculpt Technologies beats DocGo on 10 of the 15 factors compared between the two stocks.

How does DocGo compare to Burning Rock Biotech?

Burning Rock Biotech (NASDAQ:BNR) and DocGo (NASDAQ:DCGO) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings, media sentiment and valuation.

Burning Rock Biotech has higher revenue and earnings than DocGo. Burning Rock Biotech is trading at a lower price-to-earnings ratio than DocGo, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Burning Rock Biotech	$539.57M	0.33	-$7.92M	-$0.79	N/A
DocGo	$322.20M	0.17	-$182.40M	-$1.85	N/A

Burning Rock Biotech has a net margin of -10.27% compared to DocGo's net margin of -56.61%. Burning Rock Biotech's return on equity of -9.98% beat DocGo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Burning Rock Biotech	-10.27%	-9.98%	-6.69%
DocGo	-56.61%	-34.41%	-23.82%

Burning Rock Biotech has a beta of 1.49, suggesting that its share price is 49% more volatile than the S&P 500. Comparatively, DocGo has a beta of 1.02, suggesting that its share price is 2% more volatile than the S&P 500.

DocGo has a consensus price target of $2.38, indicating a potential upside of 316.45%. Given DocGo's stronger consensus rating and higher possible upside, analysts clearly believe DocGo is more favorable than Burning Rock Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Burning Rock Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
DocGo	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29

In the previous week, DocGo had 3 more articles in the media than Burning Rock Biotech. MarketBeat recorded 3 mentions for DocGo and 0 mentions for Burning Rock Biotech. Burning Rock Biotech's average media sentiment score of 0.00 equaled DocGo'saverage media sentiment score.

Company	Overall Sentiment
Burning Rock Biotech	Neutral
DocGo	Neutral

30.0% of Burning Rock Biotech shares are owned by institutional investors. Comparatively, 56.4% of DocGo shares are owned by institutional investors. 30.3% of Burning Rock Biotech shares are owned by insiders. Comparatively, 3.8% of DocGo shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Burning Rock Biotech beats DocGo on 9 of the 15 factors compared between the two stocks.

How does DocGo compare to KindlyMD?

KindlyMD (NASDAQ:NAKA) and DocGo (NASDAQ:DCGO) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, dividends, risk and media sentiment.

KindlyMD has higher earnings, but lower revenue than DocGo. DocGo is trading at a lower price-to-earnings ratio than KindlyMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
KindlyMD	$1.82M	67.14	-$52.23M	-$0.87	N/A
DocGo	$322.20M	0.17	-$182.40M	-$1.85	N/A

KindlyMD has a beta of 17.12, meaning that its stock price is 1,612% more volatile than the S&P 500. Comparatively, DocGo has a beta of 1.02, meaning that its stock price is 2% more volatile than the S&P 500.

56.4% of DocGo shares are held by institutional investors. 24.5% of KindlyMD shares are held by company insiders. Comparatively, 3.8% of DocGo shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

DocGo has a net margin of -56.61% compared to KindlyMD's net margin of -2,866.57%. KindlyMD's return on equity of -16.11% beat DocGo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
KindlyMD	-2,866.57%	-16.11%	-11.25%
DocGo	-56.61%	-34.41%	-23.82%

In the previous week, DocGo had 2 more articles in the media than KindlyMD. MarketBeat recorded 3 mentions for DocGo and 1 mentions for KindlyMD. KindlyMD's average media sentiment score of 1.02 beat DocGo's score of 0.00 indicating that KindlyMD is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
KindlyMD	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
DocGo	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

KindlyMD currently has a consensus price target of $0.75, indicating a potential upside of 323.49%. DocGo has a consensus price target of $2.38, indicating a potential upside of 316.45%. Given KindlyMD's stronger consensus rating and higher possible upside, research analysts clearly believe KindlyMD is more favorable than DocGo.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
KindlyMD	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
DocGo	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29

Summary

KindlyMD beats DocGo on 11 of the 15 factors compared between the two stocks.

How does DocGo compare to Biodesix?

DocGo (NASDAQ:DCGO) and Biodesix (NASDAQ:BDSX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.

Biodesix has a net margin of -33.26% compared to DocGo's net margin of -56.61%. DocGo's return on equity of -34.41% beat Biodesix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DocGo	-56.61%	-34.41%	-23.82%
Biodesix	-33.26%	-2,101.40%	-35.65%

DocGo has a beta of 1.02, suggesting that its share price is 2% more volatile than the S&P 500. Comparatively, Biodesix has a beta of 0.43, suggesting that its share price is 57% less volatile than the S&P 500.

In the previous week, Biodesix had 6 more articles in the media than DocGo. MarketBeat recorded 9 mentions for Biodesix and 3 mentions for DocGo. Biodesix's average media sentiment score of 0.33 beat DocGo's score of 0.00 indicating that Biodesix is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DocGo	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Biodesix	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Neutral

56.4% of DocGo shares are owned by institutional investors. Comparatively, 21.0% of Biodesix shares are owned by institutional investors. 3.8% of DocGo shares are owned by insiders. Comparatively, 23.2% of Biodesix shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

DocGo presently has a consensus price target of $2.38, indicating a potential upside of 316.45%. Biodesix has a consensus price target of $33.00, indicating a potential upside of 115.40%. Given DocGo's higher probable upside, equities research analysts clearly believe DocGo is more favorable than Biodesix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DocGo	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29
Biodesix	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Biodesix has lower revenue, but higher earnings than DocGo. Biodesix is trading at a lower price-to-earnings ratio than DocGo, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DocGo	$322.20M	0.17	-$182.40M	-$1.85	N/A
Biodesix	$88.50M	1.75	-$35.26M	-$4.06	N/A

Summary

DocGo and Biodesix tied by winning 8 of the 16 factors compared between the two stocks.

Get DocGo News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DCGO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DCGO vs. The Competition

Export

Metric	DocGo	Medical Services Industry	Medical Sector	NASDAQ Exchange
Market Cap	$56.32M	$8.21B	$6.18B	$12.29B
Dividend Yield	N/A	2.92%	2.78%	5.25%
P/E Ratio	-0.31	22.89	28.70	27.27
Price / Sales	0.17	17.54	506.88	64.14
Price / Cash	11.24	82.13	43.30	53.97
Price / Book	0.45	4.79	10.00	6.82
Net Income	-$182.40M	$183.43M	$3.54B	$332.87M
7 Day Performance	N/A	N/A	N/A	0.09%
1 Month Performance	3.73%	6.03%	4.67%	7.37%
1 Year Performance	-75.47%	2.16%	40.47%	41.10%

DocGo Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DCGO DocGo	2.6891 of 5 stars	$0.57 -10.0%	$2.38 +316.4%	-73.6%	$56.32M	$322.20M	N/A	3,568	News Coverage Upcoming Earnings
LFMD LifeMD	3.5653 of 5 stars	$4.98 +6.3%	$9.14 +83.8%	-44.1%	$239.13M	$194.05M	19.17	230	Earnings Report
AIRS AirSculpt Technologies	2.1421 of 5 stars	$3.31 +23.3%	$6.00 +81.5%	+35.2%	$232.45M	$151.82M	N/A	240	News Coverage Gap Up
BNR Burning Rock Biotech	1.1466 of 5 stars	$17.44 +2.6%	N/A	+614.7%	$187.65M	$77.16M	N/A	1,390
NAKA KindlyMD	4.1246 of 5 stars	$0.19 +9.9%	$0.75 +287.6%	N/A	$133.52M	$1.82M	N/A	N/A	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DCGO) was last updated on 5/8/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

DocGo (DCGO) Competitors